CUL4A overexpression enhances lung tumor growth and sensitizes lung cancer cells to Erlotinib via transcriptional regulation of EGFR

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Wang, Yunshan ^a,b   Zhang, Pengju ^a   Liu, Ziming ^c   Wang, Qin ^d   Wen, Mingxin ^a   Wang, Yuli ^a   Yuan, Hongtu ^e   Mao, Jian Hua ^f   Wei, Guangwei ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANDONG UNIVERSITY   (China)

^c The Fifth People's Hospital of Jinan   (China)

^d SHANDONG UNIVERSITY   (China)

^e SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^f LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

CUL4A; EGFR; Erlotinib; Lung cancer

Indexed keywords

CULLIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PROTEIN CUL4A; PROTEIN KINASE B; UNCLASSIFIED DRUG; CUL4A PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; MTT ASSAY; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; GENETIC TRANSCRIPTION; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CULLIN PROTEINS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTION, GENETIC;

EID: 84934991979     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-252     Document Type: Article

References (42)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 1, 62:10-29. 10.3322/caac.20138
2. Raine R, Wong W, Scholes S, Ashton C, Obichere A, Ambler G: Social variations in access to hospital care for patients with colorectal, breast, and lung cancer between 1999 and 2006: retrospective analysis of hospital episode statistics. BMJ 1, 340:b5479. 10.1136/bmj.b5479
3. Littlefield P, Jura N: EGFR lung cancer mutants get specialized. Proc Natl Acad Sci U S A 1, 110:15169-15170. 10.1073/pnas.1314719110
4. Liu X, Lu Y, Zhu G, Lei Y, Zheng L, Qin H, Tang C, Ellison G, McCormack R, Ji Q: The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies. J Clin Pathol 1, 66:1065-1069. 10.1136/jclinpath-2013-201728
5. Traynor AM, Weigel TL, Oettel KR, Yang DT, Zhang C, Kim K, Salgia R, Iida M, Brand TM, Hoang T, Campbell TC, Hernan HR, Wheeler DL: Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer 1, 81:138-141. 10.1016/j.lungcan.2013.03.020
6. Yamashita F, Azuma K, Yoshida T, Yamada K, Kawahara A, Hattori S, Takeoka H, Zaizen Y, Kawayama T, Kage M, Hoshino T: Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy. PLoS One 1, 8:e71356. 10.1371/journal.pone.0071356
7. Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanka T, Tajima K, Harada R, Fukuoka M, Yamamoto N: Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 1, 15:1236-1244. 10.1016/S1470-2045(14)70381-X
8. Noto A, De Vitis C, Roscilli G, Fattore L, Malpicci D, Marra E, Luberto L, D'Andrilli A, Coluccia P, Giovagnoli MR, Normanno N, Ruco L, Aurisicchio L, Mancini R, Ciliberto G: Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer. Oncotarget 2013, 4:1253-1265.
9. Lee J, Zhou P: Pathogenic Role of the CRL4 Ubiquitin Ligase in Human Disease. Front Oncol 2012, 2:21.
10. Sugasawa K: The CUL4 enigma: culling DNA repair factors. Mol Cell 1, 34:403-404. 10.1016/j.molcel.2009.05.009
11. Nag A, Bagchi S, Raychaudhuri P: Cul4A physically associates with MDM2 and participates in the proteolysis of p53. Cancer Res 1, 64:8152-8155. 10.1158/0008-5472.CAN-04-2598
12. Li B, Jia N, Kapur R, Chun KT: Cul4A targets p27 for degradation and regulates proliferation, cell cycle exit, and differentiation during erythropoiesis. Blood 1, 107:4291-4299. 10.1182/blood-2005-08-3349
13. Nishitani H, Shiomi Y, Iida H, Michishita M, Takami T, Tsurimoto T: CDK inhibitor p21 is degraded by a proliferating cell nuclear antigen-coupled Cul4-DDB1Cdt2 pathway during S phase and after UV irradiation. J Biol Chem 1, 283:29045-29052. 10.1074/jbc.M806045200
14. Han JH, Zhang H, Zhang HL, Wang ZQ, Zhou H, Zhang ZG: A Cul4 E3 Ubiquitin Ligase Regulates Histone Hand-Off during Nucleosome Assembly. Cell 1, 155:817-829. 10.1016/j.cell.2013.10.014
15. Hu J, Xiong Y: An evolutionarily conserved function of proliferating cell nuclear antigen for Cdt1 degradation by the Cul4-Ddb1 ubiquitin ligase in response to DNA damage. J Biol Chem 1, 281:3753-3756. 10.1074/jbc.C500464200
16. Chen LC, Manjeshwar S, Lu Y, Moore D, Ljung BM, Kuo WL, Dairkee SH, Wernick M, Collins C, Smith HS: The human homologue for the Caenorhabditis elegans cul-4 gene is amplified and overexpressed in primary breast cancers. Cancer Res 1998, 58:3677-3683.
17. Yasui K, Arii S, Zhao C, Imoto I, Ueda M, Nagai H, Emi M, Inazawa J: TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology 2002, 35:1476-1484. 10.1053/jhep.2002.33683
18. Schindl M, Gnant M, Schoppmann SF, Horvat R, Birner P: Overexpression of the human homologue for Caenorhabditis elegans cul-4 gene is associated with poor outcome in node-negative breast cancer. Anticancer Res 2007, 27:949-952.
19. Liu L, Lee S, Zhang J, Peters SB, Hannah J, Zhang Y, Yin Y, Koff A, Ma L, Zhou P: CUL4A abrogation augments DNA damage response and protection against skin carcinogenesis. Mol Cell 1, 34:451-460. 10.1016/j.molcel.2009.04.020
20. Hung MS, Mao JH, Xu Z, Yang CT, Yu JS, Harvard C, Lin YC, Bravo DT, Jablons DM, You L: Cul4A is an oncogene in malignant pleural mesothelioma. J Cell Mol Med 1, 15:350-358. 10.1111/j.1582-4934.2009.00971.x
21. Birner P, Schoppmann A, Schindl M, Dinhof C, Jesch B, Berghoff AS, Schoppmann SF: Human homologue for Caenorhabditis elegans CUL-4 protein overexpression is associated with malignant potential of epithelial ovarian tumours and poor outcome in carcinoma. J Clin Pathol 1, 65:507-511. 10.1136/jclinpath-2011-200463
22. Ren S, Xu C, Cui Z, Yu Y, Xu W, Wang F, Lu J, Wei M, Lu X, Gao X, Liang Y, Mao JH, Sun Y: Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer. J Mol Med 1, 90:1121-1132. 10.1007/s00109-012-0885-0
23. Melchor L, Saucedo-Cuevas LP, Munoz-Repeto I, Rodriguez-Pinilla SM, Honrado E, Campoverde A, Palacios J, Nathanson KL, Garcia MJ, Benitez J: Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes. Breast Cancer Res 1, 11:R86. 10.1186/bcr2456
24. Yang YL, Hung MS, Wang Y, Ni J, Mao JH, Hsieh D, Au A, Kumar A, Quigley D, Fang LT, Yeh CC, Xu Z, Jablons DM, You L: Lung tumourigenesis in a conditional Cul4A transgenic mouse model. J Pathol 1, 233:113-123. 10.1002/path.4352
25. Kim TY, Jackson S, Xiong Y, Whitsett TG, Lobello JR, Weiss GJ, Tran NL, Bang YJ, Der CJ: CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth. Proc Natl Acad Sci U S A 1, 110:16868-16873. 10.1073/pnas.1306358110
26. Lo YH, Ho PC, Wang SC: Epidermal growth factor receptor protects proliferating cell nuclear antigen from cullin 4A protein-mediated proteolysis. J Biol Chem 1, 287:27148-27157. 10.1074/jbc.M112.388843
27. Charpidou A, Blatza D, Anagnostou V, Syrigos KN: Review. EGFR mutations in non-small cell lung cancer-clinical implications. In Vivo 2008, 22:529-536.
28. Kawai H, Ishii A, Washiya K, Konno T, Kon H, Yamaya C, Ono I, Ogawa J: Combined overexpression of EGFR and estrogen receptor alpha correlates with a poor outcome in lung cancer. Anticancer Res 2005, 25:4693-4698.
29. Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, He X, Wang Q, Huang Y, Jen KY, LaBarge MA, You L, Kogan SC, Gray JW, Mao JH, Wei G: CUL4A Induces Epithelial-Mesenchymal Transition and Promotes Cancer Metastasis by Regulating ZEB1 Expression. Cancer Res 1, 74:520-531. 10.1158/0008-5472.CAN-13-2182
30. Oxnard GR, Binder A, Janne PA: New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 1, 31:1097-1104. 10.1200/JCO.2012.42.9829
31. Shinomiya T, Mori T, Ariyama Y, Sakabe T, Fukuda Y, Murakami Y, Nakamura Y, Inazawa J: Comparative genomic hybridization of squamous cell carcinoma of the esophagus: the possible involvement of the DPI gene in the 13q34 amplicon. Genes Chromosomes Cancer 1, 24:337-344. 10.1002/(SICI)1098-2264(199904)24:4<337::AID-GCC7>3.0.CO;2-O
32. Dohna M, Reincke M, Mincheva A, Allolio B, Solinas-Toldo S, Lichter P: Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Gene Chromosome Canc 1, 28:145-152. 10.1002/(SICI)1098-2264(200006)28:2<145::AID-GCC3>3.0.CO;2-7
33. Michiels EMC, Weiss MM, Hoovers JMN, Baak JPA, Voute PA, Baas F, Hermsen MAJA: Genetic alterations in childhood medulloblastoma analyzed by comparative genomic hybridization. J Pediat Hematol Onc 1, 24:205-210. 10.1097/00043426-200203000-00009
34. El-Mahdy MA, Zhu Q, Wang QE, Wani G, Praetorius-Ibba M, Wani AA: Cullin 4A-mediated proteolysis of DDB2 protein at DNA damage sites regulates in vivo lesion recognition by XPC. J Biol Chem 1, 281:13404-13411. 10.1074/jbc.M511834200
35. Hagiwara K, Kobayashi K: Importance of the cytological samples for the epidermal growth factor receptor gene mutation test for non-small cell lung cancer. Cancer Sci 1, 104:291-297. 10.1111/cas.12081
36. Boutayeb S, Bensouda Y, Fadoulkhair Z, Bakkraoui K, Bachouchi M, Errihani H: [Targeted therapies in digestive oncology]. Pathol Biol (Paris) 1, 60:264-268. 10.1016/j.patbio.2012.05.013
37. Cagle PT, Allen TC: Lung cancer genotype-based therapy and predictive biomarkers: present and future. Arch Pathol Lab Med 1, 136:1482-1491. 10.5858/arpa.2012-0508-RA
38. Rossi A, Pasquale R, Esposito C, Normanno N: Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients? Cancer Treat Rev 1, 39:489-497. 10.1016/j.ctrv.2012.09.001
39. Laurie SA, Goss GD: Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer. J Clin Oncol 1, 31:1061-1069. 10.1200/JCO.2012.43.4522
40. Jendrossek V: The intrinsic apoptosis pathways as a target in anticancer therapy. Curr Pharm Biotechnol 1, 13:1426-1438. 10.2174/138920112800784989
41. Mansilla S, Llovera L, Portugal J: Chemotherapeutic targeting of cell death pathways. Anticancer Agents Med Chem 1, 12:226-238. 10.2174/187152012800228805
42. Broadhead ML, Dass CR, Choong PF: Cancer cell apoptotic pathways mediated by PEDF: prospects for therapy. Trends Mol Med 1, 15:461-467. 10.1016/j.molmed.2009.08.003